RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

Sponsor: Ono Pharmaceutical Co., Ltd. • ClinicalTrials.gov ID: NCT07734116

Registry updated: 2026-10-06

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma, and to evaluate the tolerability in pediatric patients. The objective of this study is to explore the tolerability, safety, efficacy, and pharmacokinetics of ONO-4538HSC in patients with pediatric malignant solid tumors. The other objective is to exploratively investigate the efficacy and safety of ONO-4538HSC in patients with epithelioid sarcoma.

Interventions

ONO-4538HSC (Drug)
ONO-4538HSC will be administered subcutaneously once every 4 weeks.

Eligibility criteria

Inclusion Criteria: \[Cohort of pediatric malignant solid tumor Tolerability evaluation part\] 1. Patients aged ≥ 12 to \< 18 years at the time of signing the informed consent form (ICF) 2. Patients with radically/curatively unresectable advanced or metastatic solid tumor who are refractory to or intolerant to standard treatment or for which no standard treatment is available. 3. Patients with ECOG PS of 0 to 1 \[Cohort of pediatric malignant solid tumor Expansion part\] 4. Patients aged ≥ 12 to \< 18 years at the time of signing the informed consent form (ICF) 5. Patients with unresectable tumors for whom nivolumab intravenous monotherapy is indicated in adults according to the package insert 6. Patients who have at least 1 measurable lesion per RECIST guideline 7. Patients with ECOG PS of 0 to 2 \[Cohort of Epithelioid Sarcoma\] 8. Patients aged ≥ 12 years of age at the time of signing the informed consent form (ICF). However, patients aged ≥ 12 to \< 18 years may be enrolled after tolerability is confirmed in the tolerability evaluation part in the cohort of pediatric malignant solid tumor. 9. Patients who are refractory to or ineligible to at least 1 regimen of chemotherapy including doxorubicin for unresectable advanced or recurrent epithelioid sarcoma 10. Patients who have at least 1 measurable lesion per RECIST guideline 11. Patients with ECOG PS of 0 to 2 \[Common\] 12. Life expectancy ≥ 3 months at the time of enrollment Exclusion Criteria: 1. Patients with current or previous severe hypersensitivity reactions to antibody products 2. Patients with primary central nervous system tumor 3. Patients with brain or meningeal metastases. However, patients who are asymptomatic and do not require treatment can be enrolled. 4. Patients with multiple cancers 5. Patients who have previously received anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody, or other therapeutic antibodies or pharmacotherapies for regulation of T cells

Conditions

Pediatric Malignant Solid Tumor and Epithelioid Sarcoma

Locations

Chiba University Hospital — Chiba, Chiba, Japan
National Cancer Center Hospital East — Kashiwa, Chiba, Japan
Kyushu University Hospital — Fukuoka, Fukuoka, Japan
Hiroshima University Hospital — Hiroshima, Hiroshima, Japan
Hokkaido University Hospital — Sapporo, Hokkaido, Japan
Kanazawa University Hospital — Kanazawa, Ishikawa-ken, Japan
Yokohama City University Hospital — Yokohama, Kanagawa, Japan
Kyoto University Hospital — Kyoto, Kyoto, Japan
Mie University Hospital — Tsu, Mie-ken, Japan
Tohoku University Hospital — Sendai, Miyagi, Japan
Okayama University Hospital — Okayama, Okayama-ken, Japan
Osaka International Cancer Institute — Osaka, Osaka, Japan
Kindai University Hospital — Sakai, Osaka, Japan
Shizuoka Cancer Center — Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital — Chuo-ku, Tokyo, Japan

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment